Stock Report: Achillion Pharmaceuticals Inc. (ACHN) Report Updated: Jun 17, 2013 | Print This Page

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on the development of antivirals for the treatment of chronic hepatitis C infection (HCV); and the development of antibacterials for the treatment of resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise ACH-1625, a NS3 protease inhibitor that is in Phase IIa clinical trials; ACH-2684, a NS3 protease inhibitor, which is in Phase I clinical trials; ACH-2928, a NS5A inhibitor that is in Phase I clinical trials; and ACH-3102, a NS5A inhibitor, which is in Phase I clinical trials. Its pipeline of antibacterial product candidates also includes ACH-702 for the treatment of dermatologic and ophthalmic infections; and ACH-2881 for the treatment of resistant bacterial infections, including methicillin-resistant staphylococcus aureus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.